Pociredir for Sickle Cell Disease

This trial tests Pociredir, a new tablet for people with Sickle Cell Disease (SCD). The researchers aim to understand how the body absorbs the drug with or without food. Participants will be divided into two groups: one taking the tablet on an empty stomach and the other after a high-fat meal. People with SCD who have stable health and no plans for major surgeries soon might be a good fit. As a Phase 1 trial, this research focuses on understanding how Pociredir works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop all current medications, but you can continue crizanlizumab and L-glutamine if you've been on a stable dose for at least 6 months. However, you cannot take medications that affect certain liver enzymes or proteins within 14 days before starting the trial.

Research has shown that Pociredir is generally safe for people with sickle cell disease. One study found Pociredir to be safe and showed early signs of efficacy. Another study reported that Pociredir was well-tolerated at doses of 12 mg and 20 mg. These findings suggest that Pociredir is safe for humans, with no major safety issues reported so far.¹²³⁴⁵

Pociredir is unique because it offers a new approach to treating sickle cell disease by potentially improving the absorption and effectiveness of the medication through its administration under different dietary conditions. Unlike traditional treatments like hydroxyurea or blood transfusions, Pociredir is being tested in both fasted and fed states, which could optimize how the body absorbs the drug. Researchers are excited about this treatment because it could lead to more personalized and effective dosing strategies, ultimately improving patient outcomes and quality of life.

Research has shown that Pociredir holds promise for treating Sickle Cell Disease. Studies have found that Pociredir increases fetal hemoglobin (HbF), which can help lessen the disease's symptoms. One study reported that patients taking Pociredir experienced an average HbF increase of 12.2% over 12 weeks. Another study found that more than half of the participants reached HbF levels associated with fewer sickle cell crises. In this trial, participants will receive Pociredir under different conditions: one group under fasted conditions and another after a high-fat breakfast. These findings suggest that Pociredir could effectively improve outcomes for people with Sickle Cell Disease.³⁶⁷⁸⁹